A creative, purpose-driven project manager with over 12 years of global clinical trial experience, Amy Goodykoontz got her first taste of clinical research in 2008 and she’s been hooked ever since.
Over the span of her career, Ms. Goodykoontz has supported multiple Phase 1 – Phase 3 study protocols emphasizing complex study designs, including trials with single and multiple-dose escalations, central adjudication, interim analyses, long-term extensions, and data and safety monitoring boards. Ms. Goodykoontz excels in the management of specialized vendors for biomarker and genetic testing, including those that require cerebral spinal fluid analysis, positron emission tomography, magnetic field imaging, and finally, centralized rater services for cognitive and motor function assessment testing and analysis.
Dedicating her career to increasing the understanding of disorders affecting the central nervous system, Ms. Goodykoontz’s unrelenting drive to bring effective treatments to the market is only rivaled by her passion. Aligning her personal and professional interest, neurodegenerative and chronic motor deficit disorders are simply what make her tick, with an emphasis in Phase 1 – 2a Alzheimer’s Disease protocols. Ms. Goodykoontz has also managed Phase 2b studies investigating the efficacy of modified stem cells for traumatic brain injury and stroke, as well as Phase 1 Alzheimer’s disease and narcolepsy observational trials.
Ms. Goodykoontz holds a bachelor of science in microbiology from Arizona State University and a master’s degree in health administration from the University of Phoenix.
“My passion for understanding how the brain functions was ignited during my undergraduate research years at Arizona State University when my college roommate was diagnosed with a terminal brain tumor. Watching it affect his cognition, motor functions, and personality … I simply had to understand it.”
This is what drives Amy:
“After witnessing my college roommate’s struggle with a terminal brain tumor, I knew exactly what I was meant to do – bring effective treatments to the market in order to help others just like him.”
Content by Amy Goodykoontz
Hindsight is so 2020: Getting Ahead of CNS Trial Enrollment in a Rapidly Changing Clinical Landscape
The past six months have highlighted both existing and unexpected enrollment challenges, as sponsors, CROs, and sites have been pressed to evolve their recruitment strategies. Join us as Rho experts discuss their approach to adapting CNS trial enrollment to a rapidly changing clinical landscape,